Böger C, Krüger S, Behrens H M, Bock S, Haag J, Kalthoff H, Röcken C
Department of Pathology, Christian-Albrechts-University, Kiel, Germany
Department of Experimental Cancer Research, Christian-Albrechts-University, Kiel, Germany.
Ann Oncol. 2017 May 1;28(5):1005-1014. doi: 10.1093/annonc/mdx047.
Recent whole-genome sequencing identified four molecular subtypes of gastric cancer (GC), of which the subgroup of Epstein-Barr virus-associated GC (EBVaGC) showed a significant enrichment of PIK3CA mutations. We here aimed to validate independently the enrichment of PIK3CA mutations in EBVaGC of a Central European GC cohort, to correlate EBV status with clinico-pathological patient characteristics and to test for a major issue of GC, intratumoral heterogeneity.
In a first step, 484 GCs were screened for EBV and PIK3CA hot spot mutations of exon 9/20 using EBER in situ hybridization and pyrosequencing, respectively. Secondly, an extended sequencing of PIK3CA also utilizing next generation sequencing was carried out in all EBVaGCs and 96 corresponding lymph node metastases.
Twenty-two GCs were EBER-positive, all being of latency type I. Intratumoral heterogeneity of EBER-positivity was found in 18% of EBVaGCs. Twenty-three GCs held PIK3CA mutations in hot spot regions of exon 9 or 20, being significantly more common in EBVaGCs (P < 0.001). Subsequent extended sequencing of PIK3CA of EBVaGCs showed that 14% harvested three to five different PIK3CA genotypes (including wildtype) in the same primary tumor, albeit in histologically and spatially distinct tumor areas, and that intratumoral heterogeneity of PIK3CA was also present in the corresponding lymph node metastases.
Our findings unravel issues of tumor heterogeneity and illustrate that the assessment of the EBV status in tissue biopsies might carry the risk of sampling errors, which may significantly hamper adequate molecular tumor classification in a more clinical setting. Moreover, this is the first report of intratumoral heterogeneity of PIK3CA mutations in GC, and our findings lead to the conclusion that PIK3CA mutant and -wildtype tumor subclones are skilled to metastasize independently to different regional lymph nodes.
近期的全基因组测序确定了胃癌(GC)的四种分子亚型,其中爱泼斯坦-巴尔病毒相关胃癌(EBVaGC)亚组显示PIK3CA突变显著富集。我们在此旨在独立验证中欧胃癌队列中EBVaGC中PIK3CA突变的富集情况,将EBV状态与患者临床病理特征相关联,并检测胃癌的一个主要问题——肿瘤内异质性。
第一步,分别使用EBER原位杂交和焦磷酸测序对484例胃癌进行EBV和PIK3CA第9/20外显子热点突变筛查。其次,对所有EBVaGC和96个相应的淋巴结转移灶进行PIK3CA的扩展测序,同样利用下一代测序技术。
22例胃癌为EBER阳性,均为I型潜伏感染。18%的EBVaGC存在EBER阳性的肿瘤内异质性。23例胃癌在第9或20外显子热点区域存在PIK3CA突变,在EBVaGC中更为常见(P<0.001)。随后对EBVaGC的PIK3CA进行扩展测序显示,14%的原发肿瘤在同一肿瘤中收获了三到五种不同的PIK3CA基因型(包括野生型),尽管在组织学和空间上是不同的肿瘤区域,并且相应的淋巴结转移灶中也存在PIK3CA的肿瘤内异质性。
我们的研究结果揭示了肿瘤异质性问题,并表明在组织活检中评估EBV状态可能存在抽样误差风险,这在更临床的环境中可能会严重阻碍对肿瘤进行充分的分子分类。此外,这是关于胃癌中PIK3CA突变肿瘤内异质性的首次报告,我们的研究结果得出结论,PIK3CA突变型和野生型肿瘤亚克隆能够独立转移至不同的区域淋巴结。